Document text
Principal Investigator: Spyridon Stavrou
Organization: STATE UNIVERSITY OF NEW YORK AT BUFFALO
Fiscal Year: 2023
Award: $199,375
Funding agency: National Institute of Allergy and Infectious Diseases
A viral pathogen associated with severe pneumonia was recently identified as the cause of a global pandemic that has resulted in the death of over two million people. This viral pathogen was later classified as a coronavirus that was subsequently named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Currently, there is a paucity of information regarding SARS-CoV-2 infection and the cellular factors associated with it. The identification of host factors that target SARS-CoV-2 infection and the elucidation of their mechanism of action is critical for the development of SARS-CoV-2 therapeutics. It was recently shown that the Serine Incorporator (SERINC) protein family, which is comprised by 5 multipass transmembrane proteins (SERINC1-5) plays a critical role in retroviral entry, yet the role of SERINC factors on other viral infections including SARS-CoV-2 infection is currently unknown. This proposal investigates the effect of SERINC5 on SARS-CoV-2 infection. The goal of this proposal is to provide mechanistic evidence on the effect of SERINC5 on SARS-CoV-2 entry, as many times, host factors use different mechanisms to restrict viruses that belong to different viral families. Previous research has shown that human immunodeficiency virus (HIV) is potently restricted by SERINC5 in a mechanism that has not been fully elucidated. However, HIV encodes an accessory protein, Nef, which counteracts the deleterious effect of SERINC5. Similar viral proteins have been identified in other retroviruses, which demonstrates the importance of SERINC5 in retrovirus infection. Hence another aspect of this proposal is to determine a SARS-CoV-2 encoded factor that targets SERINC5 and the mechanism it utilizes to counteract SERINC5. This study will provide much needed insight into the role of a novel host factor that targets SARS- CoV-2, which is of great importance as there is not a lot of mechanistic understanding of host factors that target SARS-CoV-2. Moreover, little is known about the role of SARS-CoV-2 proteins and how they modulate the host cell; hence, the findings of this proposal will provide valuable information regarding the function of SARS-CoV-2 encoded factors. Finally, the discovery of host factors that restrict SARS-CoV-2 infection may expand the gamut of potential drug targets for the development of SARS-CoV-2 antivirals.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><21+ years old><ACE2><AIDS Virus><ARDS><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Acute Respiratory Distress><Acute Respiratory Distress Syndrome><Adult><Adult ARDS><Adult Human><Adult RDS><Adult Respiratory Distress Syndrome><Affect><Airway failure><Assay><Binding><Bioassay><Biogenesis><Biologic Assays><Biological Assay><COVID-19 anti-viral><COVID-19 antiviral><COVID-19 infection><COVID-19 therapeutics><COVID-19 virus><COVID-19 virus infection><COVID19 infection><COVID19 therapeutics><COVID19 virus><Cell Body><Cell fusion><Cells><Cessation of life><Classification><CoV-2><CoV2><Complex><Coronaviridae><Coronavirus><Coughing><DNA Molecular Biology><Da Nang Lung><Data><Death><Development><Drug Targeting><Event><Family><Fever><Genetic Alteration><Genetic Change><Genetic defect><Genome><Goals><HIV><HIV-1><HIV-I><HIV1><Host Factor><Host Factor Protein><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Infection><Integral Membrane Protein><Integration Host Factors><Intrinsic Membrane Protein><L-Serine><LAV-HTLV-III><Lymphadenopathy-Associated Virus><MOF syndrome><Malaise><Mediating><Modern Man><Molecular Biology><Molecular Interaction><Multiple Organ Dysfunction Syndrome><Multiple Organ Failure><Mutate><Mutation><Names><Origin of Life><Parvovirus><Persons><Phosphatidylserines><Picodnavirus><Play><Pneumonia><Protein Family><Proteins><Protoparvovirus><Pyrexia><Receptor Protein><Research><Research Resources><Resources><Respiratory Failure><Retroviridae><Retroviridae Infections><Retroviridae disease><Retrovirus Infections><Retroviruses><Reverse Transcription><Role><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 anti-viral><SARS-CoV-2 antiviral><SARS-CoV-2 infection><SARS-CoV-2 inhibitor><SARS-CoV-2 therapeutics><SARS-CoV2><SARS-CoV2 anti-viral><SARS-CoV2 antiviral><SARS-CoV2 infection><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 therapeutics><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Series><Serine><Serine Phosphoglycerides><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 inhibitor><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome related corona virus 2><Shock Lung><Shortness of Breath><Sphingolipids><Stiff lung><Surface><Systematics><Transmembrane Protein><Transmembrane Protein Gene><Viral><Viral Diseases><Viral Gene Products><Viral Gene Proteins><Viral Genome><Viral Proteins><Virus><Virus Diseases><Virus Replication><Virus-HIV><Virus-Retrovirus><Wuhan coronavirus><adulthood><angiotensin converting enzyme 2><angiotensin converting enzyme II><anti-viral development><anti-viral drug development><anti-viral therapeutic development><anti-viral therapy development><antiviral development><antiviral drug development><antiviral therapeutic development><antiviral therapy development><block SARS-CoV-2><block severe acute respiratory syndrome coronavirus 2><block viral entry><common symptom><corona virus><coronavirus disease 2019 anti-viral><coronavirus disease 2019 antiviral><coronavirus disease 2019 infection><coronavirus disease 2019 therapeutics><coronavirus disease 2019 virus><coronavirus disease-19 virus><current pandemic><developing anti-viral agent><developing anti-viral drug><developing anti-viral therapeutic><developing anti-viral therapy><developing antiviral agent><developing antiviral drug><developing antiviral therapeutic><developing antiviral therapy><developmental><domain mapping><febrile><febris><genome mutation><hCoV19><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inhibit SARS-CoV-2><inhibit severe acute respiratory syndrome coronavirus 2><inhibit viral entry><insight><member><multiorgan failure><multiple organ system failure><mutant><nCoV2><name><named><naming><novel><pandemic><pandemic disease><parvovirus group><pathogenic virus><present pandemic><receptor><receptor binding><receptor bound><severe acute respiratory syndrome coronavirus 2 anti-viral><severe acute respiratory syndrome coronavirus 2 antiviral><severe acute respiratory syndrome-CoV><social role><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic agent development><therapeutic development><therapeutic target><therapeutics against COVID-19><therapeutics against COVID19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><viral entry blocker><viral entry inhibitor><viral infection><viral multiplication><viral pathogen><viral replication><virus genome><virus infection><virus multiplication><virus pathogen><virus protein><virus-induced disease><wet lung>